Get the Stockscreener App
0.4552
5.25%
-0.0252
Inspiremd Inc stock is traded at $0.4552, with a volume of 94,627.
It is down -5.25% in the last 24 hours and down -40.88% over the past month.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
See More
Previous Close:
$0.4804
Open:
$0.4783
24h Volume:
94,627
Relative Volume:
0.59
Market Cap:
$21.32M
Revenue:
$10.85M
Net Income/Loss:
$-51.31M
P/E Ratio:
-0.6176
EPS:
-0.737
Net Cash Flow:
$-36.77M
1W Performance:
-12.63%
1M Performance:
-40.88%
6M Performance:
-66.28%
1Y Performance:
-80.87%
1-Day Range:
$0.45
$0.4849
1-Week Range:
$0.45
$0.5738
52-Week Range:
$0.45
$2.42
Inspiremd Inc Stock (NSPR) Company Profile
Name
Inspiremd Inc
Sector
Industry
Phone
(888) 776-6804
Address
6303 WATERFORD DISTRICT DRIVE, MIAMI
Compare NSPR vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
Inspiremd Inc
|
0.4552 | 21.32M | 10.85M | -51.31M | -36.77M | -0.737 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Inspiremd Inc Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
Inspiremd Inc Stock (NSPR) Latest News
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 LevelButterfly Setup - https://www.siam.in/
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 LevelMomentum Trade - https://www.dars.gov.et/
InspireMD (NASDAQ:NSPR) Will Have To Spend Its Cash Wisely - Simply Wall Street
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com UK
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com Nigeria
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com UK
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan
InspireMD amends certain Series J, Series K warrants - Medical Buyer
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - kalkinemedia.com
InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - manilatimes.net
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - GlobeNewswire Inc.
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
InspireMD amends warrants tied to FDA approval timeline - Investing.com
Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga
InspireMD announces inducement grants - Medical Buyer
Inspiremd Stock Price Forecast. Should You Buy NSPR? - StockInvest.us
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
InspireMD Inc. (NSPR) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - valueresearchonline.com
InspireMD Inc. Series B Warrants (NSPRZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc. Series B Warrants (NSPRZ) Peer Comparison – Compare with Others - Value Research
InspireMD Earnings Call: Recall Pain, Regulatory Potential - TipRanks
InspireMD Inc. Series B Warrants (NSPRZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusETF Creation Redemption - siam.in
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusStandard Deviation - dars.gov.et
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $3 - Moomoo
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate - Sci-Tech Today
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD total revenue down 0.4% to USD 1,771,000 in Q2 2026 - Medical Buyer
Form 8K InspireMD Inc For: 17 August By Investing.com - Investing.com South Africa
InspireMD Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
InspireMD Q2 revenue holds at $1.8 million - grafa.com
InspireMD, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com Nigeria
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com
InspireMD Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
Inspiremd Inc Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inspiremd Inc Stock (NSPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | Chief Commercial Officer |
May 19 '26 |
Sale |
1.01 |
22,778 |
23,006 |
1,053,882 |
| Stuka Paul | Director |
May 14 '26 |
Buy |
1.15 |
5,000 |
5,750 |
647,871 |
| Stuka Paul | Director |
May 13 '26 |
Buy |
1.16 |
10,000 |
11,575 |
642,871 |
| Slosman Marvin | CEO and President |
May 12 '26 |
Buy |
1.20 |
21,000 |
25,200 |
3,556,658 |
| Stuka Paul | Director |
May 11 '26 |
Buy |
1.19 |
10,000 |
11,900 |
632,871 |
| Stuka Paul | Director |
May 08 '26 |
Buy |
1.16 |
65,626 |
76,126 |
622,871 |
| ROUBIN GARY S | Director |
May 07 '26 |
Buy |
1.18 |
90,000 |
106,200 |
834,478 |
| Ward Scott R. | Director |
May 07 '26 |
Buy |
1.15 |
73,255 |
84,243 |
237,096 |
| Stuka Paul | Director |
May 07 '26 |
Buy |
1.15 |
6,378 |
7,335 |
531,599 |
| Ward Scott R. | Director |
May 06 '26 |
Buy |
1.15 |
15,995 |
18,394 |
163,841 |
7.18%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):